Literature DB >> 14605330

4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly.

Tiny Hoekstra1, Johanna M Geleijnse, Cornelis Kluft, Erik J Giltay, Frans J Kok, Evert G Schouten.   

Abstract

BACKGROUND AND
PURPOSE: Plasminogen activator inhibitor type 1 (PAI-1) is the main inhibitor of fibrinolysis, and high levels may increase the risk of cardiovascular disease. The 4G/5G polymorphism affects PAI-1 gene transcription with lower levels of plasma PAI-1 in the presence of the 5G allele. We investigated whether plasma PAI-1 and 4G/5G genotype would predict the occurrence of cardiovascular events at old age.
METHODS: Relative risks for cardiovascular events and all-cause mortality were obtained in strata of PAI-1 activity and 4G/5G genotype in a population-based study of 637 Dutch elderly with 7.8 years of follow-up.
RESULTS: The 4G/4G genotype was associated with a decreased risk of stroke (relative risk [RR]=0.4; 95% CI, 0.2 to 0.9), transient ischemic attack (RR=0.3; 95% CI, 0.1 to 0.8), and cardiovascular mortality (RR=0.5; 95% CI, 0.3 to 1.0) after adjustment for age, sex, and time of blood sampling. 4G carriers had an increased risk of myocardial infarction, but this was not statistically significant. Subjects with high plasma PAI-1 activity were at increased risk of stroke (RR=3.3 in highest versus lowest tertile; 95% CI, 1.5 to 7.1), cardiovascular mortality (RR=2.3; 95% CI, 1.2 to 4.4), and all-cause mortality (RR=1.5; 95% CI, 1.1 to 2.1).
CONCLUSIONS: Our results provide support for a protective effect of the 4G allele against stroke, which is notable given the direct relationship between stroke and PAI-1 activity. We hypothesize that a local increase in tissue PAI-1 associated with the 4G allele may stabilize plaques, thereby reducing the risk of cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605330     DOI: 10.1161/01.STR.0000098004.26252.EB

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

Review 1.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 2.  Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Authors:  I B Kovacs; D A Gorog; J Yamamoto
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

3.  Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis.

Authors:  M Bonyadi; Z Shaghaghi; M Haghi; S Dastgiri
Journal:  Eur J Pediatr       Date:  2012-10-05       Impact factor: 3.183

4.  PAI-1 polymorphism as a cause of severe high altitude associated arteriovenous thrombosis.

Authors:  Velu Nair; Uday Yanamandra; Rai Kumud; Kanjakya Ghosh
Journal:  BMJ Case Rep       Date:  2016-11-23

5.  Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery.

Authors:  Gonzalo Sirgo; José Luis Pérez-Vela; Pablo Morales; Manuel Del Rey; Joan Vendrell; Cristina Gutierrez; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-03-01       Impact factor: 17.440

6.  Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke.

Authors:  Adriano de Paula Sabino; Daniel Dias Ribeiro; Caroline Pereira Domingueti; Mariana Silva Dos Santos; Telma Gadelha; Luci Maria Santana Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  Mol Biol Rep       Date:  2011-03-04       Impact factor: 2.316

7.  Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults.

Authors:  Marius Ringelstein; Alexander Jung; Klaus Berger; Monika Stoll; Katharina Madlener; Christof Klötzsch; Felix Schlachetzki; Erwin Stolz
Journal:  J Neurol       Date:  2012-04-12       Impact factor: 4.849

Review 8.  Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.

Authors:  Mohsen Maleknia; Saeid Shahrabi; Majid Ghanavat; Tina Vosoughi; Najmaldin Saki
Journal:  Mol Biol Rep       Date:  2020-05-30       Impact factor: 2.316

9.  Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.

Authors:  C Nafría; I Fernández-Cadenas; M Mendioroz; S Domingues-Montanari; M Hernández-Guillamón; J Fernández-Morales; A Del Río-Espínola; D Giralt; L Deu; P Delgado; A Rosell; J Montaner
Journal:  Stroke Res Treat       Date:  2011-06-09

10.  Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants.

Authors:  Paul Bentley; George Peck; Liam Smeeth; John Whittaker; Pankaj Sharma
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.